Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: (abbreviated)~1. The patient has a diagnosis cervical cancer.~2. The patient understands the nature and purpose of this study and the study procedures and has signed informed consent.~3. The patient is aged \> 18 years.~4. The patient must be both chemo- and radiotherapy (RT) naïve. NB: previously low voltage RT or electron RT for non-melanoma skin cancers is allowed.~5. The patient is scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks.~6. Brachy therapy is scheduled to be initiated after the third cycle of weekly cisplatin, and preferentially after the fifth week of treatment.~7. Chemotherapy with an emetic risk potential of minimal or mild (up to 30%) is allowed on days 1-4 (see ref. 14).~8. The patient has a WHO Performance Status of ≤ 2.~Exclusion Criteria: (abbreviated)~1. The patient has a current malignant diagnosis other than cervical cancer, with exception of non-melanoma skin cancers.~2. The patient is aged \< 18 years.~3. The patient is scheduled to receive less than five weeks of fractionated radiotherapy and concomitant weekly cisplatin.~4. Brachy therapy is planned to be initiated before the third cycle of weekly cisplatin.~5. The patient has been previously treated with radiotherapy, and/or chemotherapy, with exception of treatment with low voltage RT or electron RT for non-melanoma skin cancers .~6. The patient has a WHO Performance Status of \> 2.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fosaprepitant dimeglumine (Type: ACTIVE_COMPARATOR): None
- Saline water (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).